The dengue virus, a formidable global health threat, demands innovative vaccination strategies tailored to diverse epidemiological contexts. This article delves into the complexities of dengue vaccination, emphasizing the importance of context-specific approaches. The dengue virus, with its four antigenically distinct serotypes, poses a significant challenge in tropical and subtropical regions, where Aedes mosquitoes are the primary vector. The disease's rapid spread, coupled with urbanization and climate change, necessitates a nuanced understanding of transmission dynamics and the development of targeted vaccination programs.
The first dengue vaccine, CYD-TDV (Dengvaxia), faced implementation hurdles due to pre-vaccination screening requirements, limiting its accessibility. The second licensed vaccine, TAK-003 (Qdenga), offers a more flexible approach, administered as a two-dose series without the need for pre-vaccination screening. Its efficacy is higher in individuals with prior dengue exposure, providing robust protection against DENV-2 but showing no efficacy against DENV-3 in seronegative individuals.
The World Health Organization (WHO) recommends TAK-003's use in high-transmission settings, defined by a seroprevalence of 60% or higher by age nine. Thailand, meeting these criteria, utilized a dynamic transmission model to evaluate various vaccination strategies, including routine childhood vaccination, catch-up campaigns, and integration with existing school-based programs. These efforts yielded substantial reductions in symptomatic and severe dengue cases, with routine vaccination of children aged 6, combined with catch-up cohorts, proving the most cost-effective.
In contrast, Singapore's lower transmission setting and different age distribution of disease burden call for tailored approaches. Modeling suggests that vaccinating individuals aged 17-30 years would maximize case reduction, while targeting those aged 51-70 years would yield the greatest reduction in hospitalizations. This highlights the need for global recommendations to adapt to local transmission patterns.
Brazil, the first country to introduce TAK-003 programmatically, reported positive real-world data during the 2024 dengue outbreak. The vaccine demonstrated an adjusted effectiveness of 50% after the first dose and 62% after the second dose against symptomatic dengue. However, cost-effectiveness analyses for the Brazilian setting are still limited, and no benefit-risk assessments or vaccine effectiveness data are available for travelers.
Brazil has also licensed a third dengue vaccine, Butantan-DV, a single-dose candidate evaluated in a large five-year trial. This vaccine is currently unavailable globally due to marketing agreements with Merck, while Merck and independent developers in India conduct Phase 3 trials of dengue vaccines based on the same virus backbone. Global licensure is expected to take several years.
In conclusion, dengue-endemic countries must carefully consider the deployment of TAK-003, the only available dengue vaccine globally. When aligned with local epidemiology and health system priorities, TAK-003 can significantly reduce dengue burden. Achieving high vaccine coverage is crucial, and future research should focus on real-world effectiveness, particularly in seronegative populations, and the durability of protection. Flexible, data-driven modeling approaches will be essential for context-specific decision-making as more countries consider vaccine introduction.
